1Groffen J,Stephensn JR,Heisteikamp N,et al.Philadelphia chromosomal breakponits are clustered within a limited region,bcr,on chromosome 22[J].Cell,1984,36:93 ～ 99
2Aethur CK,Apperley JF,Guo AP,et al.Cyrogenetic events after bone marrow transplantation for chronic myeloid leukemia in chronic phase[J].Blood,1988,71:1179
3Chase A,Grand F,Zhang JG,et al.Factors influencing the false positive and negative rates of BCR-ABL fluorescence in-situ hybridization[J].Genes Chromosom Cancer,1997,18:246 ～ 253
4Guo JQ,Lian JY,Xian YM,et al.BCR-ABL protein expression in peripheral blood cells of chronic myelogenous leukemia patients undergoing therapy[J].Blood,1994,83:3629 ～ 3637
5Roth MS,Antin JH,Ash R,et al.Prognostic significance of Philadelphia chromosome positive cells detected by the polymerase chain reaction after allogeneic bone marrow transplant for chronic myelogenous leukemia[J].Blood,1992,79:276
6Miyamura K,Tahara T,Tanimoto M,et al.Long persistent bcr-ab1 positive transcript detected by polymerase chain reaction after marrow transplant for chronic myelogenous leukemia without clinical relapse:A study of 64 patients[J].Blood,1993,81:1089
7Biernaux C,Loos M,Sels G,et al.Detection of major bcr-ab1 gene expression at a very low level in blood cells of some healthy individuals[J].Blood,1995,86:3118
8Guo q,Lin h,Kantarjian H,et al.Comparison of competitive-nested pcr and real-time pcr in detecting bcr-ale fusion transcripts in chronic myeloid leukemia patients[J].Leukemia,2002,16:2447
9Mensink E,Locht AVD,Schattenberg A,et al.Quantitation of minimal residual disease in philadelphia chromosome positive chronic myeloid leukaemia patients using real-time quantitative RT-PCR[J].British Journal of Haematology,1998,102:768
10Saffroy R,Lemoine A,Brezillon P,et al.Real-time quantitation of bcr-ab1 transcripts in haematological malignancies[J].Eur J Haematol,2000,65:258
二级参考文献10
1Gu BW, Hu J, Xu L, et al. Feasibility and clinical significance of real-time quantitative RT-PCR assay of PML-RARα fusion transcript in patients with acute promyelocytic leukemia. Hemato J, 2001,2: 330-340.
2Lin F, van Rhee F, Goldman JM, et al. Kinetics of increasing BCR-ABL transcript numbers in chronic myeloid leukemia patients who relapse after bone marrow transplantation. Blood,1996, 87:4473-4478.
3Merx K, Muller MC, Kreil S, et al. Early reduction of BCR-ABL mRNA transcript levels predicts cytogenetic response in chronic phase CML patients treated with imatinib after failure of interferon alpha. Leukemia, 2002,16:1579-1583.
5Lion T. Clinical implications of qualitative and quantitative polymerase chain reaction analysis in the monitoring of patients with chronic myelogenous leukemia. Bone Marrow Transplant, 1994, 14:505-509.
6Elmaagacli AH, Beelen DW, Opalka B, et al. The amount of BCR-ABL fusion transcripts detected by the real-time quantitative polymerase chain reaction method in patients with Philadelphia chromosome positive chronic myeloid leukemia correlates with the disease stage. Ann Hematol, 2000,79:424-431.
7Neumann F, Herold C, Hildebrandt B, et al. Quantitative real-time reverse-transcription polymerase chain reaction for diagnosis of BCR-ABL positive leukemias and molecular monitoring following allogeneic stem cell transplantation. Eur J Haematol, 2003,70:1-10.
8Branford S, Hughes TP, Rudzki Z. Monitoring chronic myeloid leukaemia therapy by real-time quantitative PCR in blood is a reliable alternative to bone marrow cytogenetics. Br J Haematol, 1999,107:587-599.
9Muller MC, Gattermann N, Lahaye T, et al. Dynamics of BCR-ABL mRNA expression in first-line therapy of chronic myelogenous leukemia patients with imatinib or interferon alpha/ara-C. Leukemia, 2003,17:2392-2400.
10Branford S, Rudzki Z, Harper A, et al. Imatinib produces significantly superior molecular responses compared to interferon alpha plus cytarabine in patients with newly diagnosed chronic myeloid leukemia in chronic phase. Leukemia, 2003,17:2401-2409.
1Paietta E. Minimal residual disease in acute myeloid leukemia: coming of age [J]. Hematol Am Soc Hematol Educ Program, 2012,2012:35-42.
2Braggemann M, Schrauder A, Raff T, et al. Standardized MRD quantification in European ALL trials : proceedings of the Second International Symposium on MRD assessment in Kiel, Gemlany, 1 8- 20 September 2008[J]. Leukemia,2010,24( 3):521-535.
3Gabert J, Beillard E, van der Velden VH, et al. Standardization and quality control studies of real-time quantitative reverse tran- scriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia-a Europe Against Cancer program[J]. Leukemia, 2003,17 (12) : 2318-2357.
4van Dongen JJ, van der Velden VH, Braggemann M, et al. Mini mal residual disease diagnostics in acute lymphoblastic leuke mia: need for sensitive, fast, and standardized technologies [J] Blood ,2015,125(26) : 3996-4009.
5Pongers-Willemse MJ, Verhagen OJ, Tibbe G J, et al. Real-time quantitative PCR for the detection of minimal residual disease in acute lymphoblastic leukemia using junctional region specific TaqMan probes [ J ]. Leukemia, 1998,12 (12) : 2006-2014.
6Coustan-Smith E, Sancho J, Hancock ML, et al. Use of peripher- al blood instead of bone marrow to monitor residual disease in children with acute lymphoblastic leukemia [J]. Blood, 2002, 100(7) :2399-2402.
7Coustan-Smith E, Song G, Clark C,et al. New markers for min- imal residual disease detection in acute lymphoblastic leuke- mia [ J ]. Blood, 2011,117 (23) : 6267-6276.
8Buceisano F, Maurillo L, Del Princ, ipe MI, et al. Prognostic and therapeutic implications of minimal residual disease detection in acute myeloid leukemia [ J ]. Blood, 2012, 119 (2) : 332-341.
9Conter V, Bartram CR, Valsecchi MG, et al. Molecular re- sponse to treatment redefines ALL prognostic factors in chil- dren and adolescents with B-cell precursor acute lymphoblas- tie leukemia: results in 3184 patients of the AIEOPBFM ALL 2000 study[J]. Blood ,2010, 115(16) :3206-3214.
10Schrappe M, Valsecchi MG, Bartram CR, et al. Late MRD re- sponse determines relapse risk overall and in subsets of child- hood T-cell ALL: results of the AIEOP-BFM-ALL 2000 study[J]. Blood, 2011,118 ( 8 ) : 2077-2084.
